Capricor Therapeutics, Inc. (CAPR)
Automate Your Wheel Strategy on CAPR
With Tiblio's Option Bot, you can configure your own wheel strategy including CAPR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CAPR
- Rev/Share 0.3805
- Book/Share 2.797
- PB 3.9864
- Debt/Equity 0.0098
- CurrentRatio 6.5475
- ROIC -0.4331
- MktCap 509641970.0
- FreeCF/Share -1.0337
- PFCF -10.803
- PE -9.2409
- Debt/Assets 0.0081
- DivYield 0
- ROE -0.6242
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CAPR | Roth Capital | -- | Buy | -- | $31 | May 20, 2025 |
| Initiation | CAPR | Piper Sandler | -- | Overweight | -- | $35 | Oct. 21, 2024 |
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Shareholders to Inquire about Securities Investigation
Published: June 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ:CAPR). Investors who purchased Capricor securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CAPR.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Stockholders to Inquire about Securities Investigation
Published: May 29, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ:CAPR). Investors who purchased Capricor securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CAPR.
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Capricor Therapeutics, Inc. (CAPR) and Encourages Investors to Learn More About the Investigation
Published: May 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ:CAPR). Investors who purchased Capricor securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CAPR.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ:CAPR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ:CAPR). Investors who purchased Capricor securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CAPR.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Investors to Inquire about Securities Investigation
Published: May 23, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ:CAPR). Investors who purchased Capricor securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CAPR.
Read More
Capricor Therapeutics' Buy Thesis Ahead Of Deramiocel PDUFA Date
Published: May 23, 2025 by: Seeking Alpha
Sentiment: Positive
Capricor Therapeutics basically has two platforms: Deramiocel CDC therapy and the StealthX exosome platform. However, its flagship candidate is undoubtedly Deramiocel, which has so far secured a PDUFA date for August 31, 2025. Deramiocel's Phase II and extension trials in over 250 DMD patients suggest this candidate has very favorable safety and efficacy for cardiomyopathy DMD.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Investors to Reach Out
Published: May 22, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ:CAPR). Investors who purchased Capricor securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CAPR.
Read More
Capricor: High-Reward DMD Treatment Bet With Strong Data And Looming FDA Decision
Published: May 22, 2025 by: Seeking Alpha
Sentiment: Positive
Capricor's lead asset, deramiocel, targets DMD-related cardiomyopathy and faces key FDA milestones (ADCOM, PDUFA) in 2025. A strong cash position and partnership with Nippon Shinyaku provide financial stability but limit direct revenue potential from U.S. and Japan sales. Clinical data shows deramiocel slows disease progression by 52%, but regulatory approval and market adoption remain uncertain.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Stockholders to Reach Out
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ:CAPR). Investors who purchased Capricor securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CAPR.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Stockholders to Connect
Published: May 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ:CAPR). Investors who purchased Capricor securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CAPR.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
Published: May 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ:CAPR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Published: May 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ:CAPR). Investors who purchased Capricor securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CAPR.
Read More
Securities Investigation: Levi & Korsinsky Investigates Capricor Therapeutics, Inc. (CAPR) on Behalf of Investors
Published: May 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Capricor Therapeutics, Inc. ("Capricor Therapeutics, Inc.") (NASDAQ:CAPR) concerning possible violations of federal securities laws. Capricor issued a press release on May 5, 2025, announcing that after "the completion of a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) for the Company's Biologics License Application (BLA) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy", the FDA had "confirmed its intent to hold …
Read More
CAPR STOCK ALERT: Levi & Korsinsky Notifies Capricor Therapeutics, Inc. Investors of an Ongoing Investigation
Published: May 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Capricor Therapeutics, Inc. ("Capricor Therapeutics, Inc.") (NASDAQ:CAPR) concerning possible violations of federal securities laws. Capricor issued a press release on May 5, 2025, announcing that after "the completion of a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) for the Company's Biologics License Application (BLA) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy", the FDA had "confirmed its intent to hold …
Read More
ATTENTION CAPR SHAREHOLDERS: Investors Who Lost Money on Capricor Therapeutics, Inc. are Urged to Contact Levi & Korsinsky about an Ongoing Investigation
Published: May 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Capricor Therapeutics, Inc. ("Capricor Therapeutics, Inc.") (NASDAQ:CAPR) concerning possible violations of federal securities laws. Capricor issued a press release on May 5, 2025, announcing that after "the completion of a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) for the Company's Biologics License Application (BLA) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy", the FDA had "confirmed its intent to hold …
Read More
Shareholders that lost money on Capricor Therapeutics, Inc. (CAPR) should contact Levi & Korsinsky about Securities Fraud Investigation - CAPR
Published: May 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Capricor Therapeutics, Inc. ("Capricor Therapeutics, Inc.") (NASDAQ:CAPR) concerning possible violations of federal securities laws. Capricor issued a press release on May 5, 2025, announcing that after "the completion of a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) for the Company's Biologics License Application (BLA) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy", the FDA had "confirmed its intent to hold …
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Capricor Therapeutics, Inc. (CAPR)
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Capricor Therapeutics, Inc. ("Capricor Therapeutics, Inc.") (NASDAQ:CAPR) concerning possible violations of federal securities laws. Capricor issued a press release on May 5, 2025, announcing that after "the completion of a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) for the Company's Biologics License Application (BLA) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy", the FDA had "confirmed its intent to hold …
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ:CAPR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the first quarter ended March 31, 2025, after the market close on Tuesday, May 13, 2025. Management will then host a webcast and conference call at 4:30 p.m.
Read More
Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Published: March 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
--Preservation of Skeletal Muscle Function Shown Over 3 Years Resulting in 52% Slowing of Disease-- --Data Presented at the 2025 Muscular Dystrophy Association (MDA) Conference--
Read More
FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment
Published: March 10, 2025 by: PRNewsWire
Sentiment: Neutral
PARAMUS, N.J. , March 10, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd.
Read More
Capricor Therapeutics to Present at Leerink's Global Healthcare Conference 2025
Published: March 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that Capricor management will participate in one-on-one investor meetings and provide a corporate update at Leerink's Global Healthcare Conference 2025, taking place March 10-12, 2025 in Miami, Florida.
Read More
Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition
Published: March 04, 2025 by: Benzinga
Sentiment: Positive
On Tuesday, the FDA accepted for review Capricor Therapeutics Inc's CAPR Biologics License Application for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy.
Read More
Capricor Therapeutics: Heavily Derisked After BLA Submission And OLE Data
Published: February 23, 2025 by: Seeking Alpha
Sentiment: Positive
Capricor Therapeutics has filed a BLA for deramiocel, showing promising results in slowing cardiac dysfunction in DMD cardiomyopathy, with strong FDA recognition. Deramiocel's efficacy was demonstrated in the HOPE-2 trials, with significant improvements in PUL 1.2 scores and positive long-term benefits in PUL 2.0 and LVEF measures. Financially, Capricor is well-positioned with a strong cash runway, strategic partnerships, and projected significant revenue from deramiocel sales by 2030.
Read More
About Capricor Therapeutics, Inc. (CAPR)
- IPO Date 2007-02-13
- Website https://www.capricor.com
- Industry Biotechnology
- CEO Dr. Linda Marbán Ph.D.
- Employees 160